Business Description
Spyre Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00773J2024
Total Employee Number:
112Description
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.88 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 48.1 | |||||
3-Year EPS without NRI Growth Rate | 55.9 | |||||
3-Year FCF Growth Rate | 51.9 | |||||
3-Year Book Growth Rate | -28.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -21.89 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 82.31 | |||||
9-Day RSI | 73.54 | |||||
14-Day RSI | 69.74 | |||||
3-1 Month Momentum % | 48.86 | |||||
6-1 Month Momentum % | 155.86 | |||||
12-1 Month Momentum % | 374.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.97 | |||||
Quick Ratio | 8.97 | |||||
Cash Ratio | 8.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -210.4 | |||||
Shareholder Yield % | -0.11 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -32.28 | |||||
ROA % | -28.44 | |||||
ROIC % | -573.22 | |||||
3-Year ROIIC % | -843.51 | |||||
ROCE % | -42.98 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 14.96 | |||||
Price-to-Tangible-Book | 14.96 | |||||
EV-to-EBIT | -32.7 | |||||
EV-to-EBITDA | -32.7 | |||||
EV-to-FCF | -42.57 | |||||
| Price-to-Net-Current-Asset-Value | 14.96 | |||||
| Price-to-Net-Cash | 11.89 | |||||
Earnings Yield (Greenblatt) % | -3.06 | |||||
FCF Yield % | -2.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Spyre Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.919 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 69.97 | ||
| 14-Day RSI | 69.74 | ||
| 14-Day ATR (€) | 2.162982 | ||
| 20-Day SMA (€) | 77.65 | ||
| 12-1 Month Momentum % | 374.64 | ||
| 52-Week Range (€) | 12.3 - 86.5 | ||
| Shares Outstanding (Mil) | 86.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Spyre Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Spyre Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-04 | In 115 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 24 days | ||
| Guidance call for 2026 | 2026-06-08 10:00 | 67.00 (+0.00%) | ||
| Guidance call for 2026 | 2026-06-03 12:15 | 59.50 (+0.00%) | ||
| General meeting for 2026 | 2026-05-27 12:00 | 64.00 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 59.00 (+1.72%) | ||
| Spyre Therapeutics SPY001 Part A Induction Topline Results | 2026-04-13 08:00 | 44.00 (+0.00%) | ||
| Leerink Global Healthcare Conference | 2026-03-09 08:40 | 34.80 (+0.00%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 15:10 | 35.80 (+0.00%) | ||
| Annual report for 2025 | 2026-02-19 | 30.20 (+0.00%) |
Show
Entries
Spyre Therapeutics Inc Frequently Asked Questions
What is Spyre Therapeutics Inc(FRA:3920)'s stock price today?
The current price of FRA:3920 is €86.00. The 52 week high of FRA:3920 is €86.50 and 52 week low is €12.30.
When is next earnings date of Spyre Therapeutics Inc(FRA:3920)?
The next earnings date of Spyre Therapeutics Inc(FRA:3920) is 2026-08-05 Est..
Does Spyre Therapeutics Inc(FRA:3920) pay dividends? If so, how much?
Spyre Therapeutics Inc(FRA:3920) does not pay dividend.
Press Release
Articles on Spyre Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers